Scientists are redesigning psychedelics for mental health benefits with fewer risks. At the UC Davis IPN, Director David Olson is innovating drugs for neural growth without adverse effects. Discover how science is transforming mental health treatments! mercurynews.com/2023/12/12/new…

Exciting news! The IPN is gearing up to launch its inaugural newsletter! Sign up now to stay in the loop and be among the first to receive exclusive updates, groundbreaking research, and more! neurotherapeutics.ucdavis.edu/news-1

Cheers to Dr. Tina Kim (tina kim), a UC Davis Center for Neuroscience Core Member and IPN Affiliate, on making MIT Tech Review's Innovators Under 35 list! Huge congrats! UC Davis Neuroscience Consortium UC Davis UC Davis Health UC Davis Neurology innovatorsunder35.com/the-list/chris…

The Institute for Psychedelics and Neurotherapeutics will be sending out their first newsletter soon. If you are interested in #psychedelics or #neurotherapeutics and would like to receive a copy, please sign up by clicking on the link on this page: neurotherapeutics.ucdavis.edu/news-1

Within #psychedelic science, the debate lingers: Is it mind-blowing experiences or powerful #molecules that spur change? Join To The Best Of Our Knowledge to hear David E. Olson's take. Also available on Spotify! youtu.be/JunhDmkrM88?si…

From #marijuana legalization to the groundbreaking potential of #psychedelics in #psychiatry— John Gray and a wave of researchers are reshaping #psychiatric treatments. A paradigm shift in how we approach mental health may just be on the horizon. cleveland.com/news/2023/11/a…

Want a preview of what you'll find in Institute for Psychedelics and Neurotherapeutics’s first newsletter? Check out “A View Inside: How #Psychedelics Promote Neuroplasticity” and scroll down to sign up for the newsletter here: lettersandscience.ucdavis.edu/news/inside-vi… #health #neurotherapeutics #chemistry #brainhealth

IPN director Olson Lab was interviewed for this PNAS news feature on the mechanisms of psychedelics pnas.org/doi/10.1073/pn…

Institute for Psychedelics and Neurotherapeutics Director Olson Lab talks about psychedelics and nonhallucinogenic psychoplastogens on the The University of Chicago's Big Brains podcast news.uchicago.edu/psychedelics-w…

Check out the latest IPN paper in J. Med. Chem. on the development of psychoplastogenic DYRK1A inhibitors with potential for treating Alzheimer's disease especially early-onset Alzheimer's disease associated with Down Syndrome pubs.acs.org/doi/10.1021/ac….

The newest research from IPN Director Olson Lab and team suggests that tropane analogs can promote #neuroplasticity with fewer side effects than compounds like scopolamine. Read more here: pubs.acs.org/doi/10.1021/ac…

The closure of the 1st UK #psychedelic-assisted therapy clinic underscores the need for developing low-cost compounds that can be safely used at home. Read more in this BBC article: bbc.in/3WkqS11 Follow Institute for Psychedelics and Neurotherapeutics to learn more about psychedelic-inspired compounds.

A new study published in nature reveals how #psilocybin, the active compound in magic mushrooms, can profoundly impact the human brain. Check out the full study! nature.com/articles/s4158… #Psychedelics #MentalHealth #NeuroResearch #Psilocybin #BrainHealth

The IPN is hiring a Director of Pharmacology. Join our team and play a key role in advancing cutting-edge research and innovative treatments in mental health. Apply now and help shape the future of psychedelic research! Learn more and #applynow: recruit.ucdavis.edu/JPF06614

IPN faculty affiliate tina kim and team just published in Nature Methods about a protein-based tool expected to aid in identifying how #psychedelics impact brain disorders by tagging neurons activated by psychedelics. nature.com/articles/s4159…